Products & Tech | Page 35 of 63

FDA Clears Roche’s Accu-Chek Combo System

Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Accu-Chek Combo system for insulin pump therapy. The Accu-Chek Combo system seamlessly combines a blood glucose meter with an insulin pump, which are able to exchange data in both directions via Bluetooth wireless technology.

Gary Scheiner Comes Through

I received a new Medtronic pump today, almost three days after mine broke. While I was waiting for a new pump, the wonderful diabetes educator,…

A Review of VerioIQ, New Blood Glucose Meter from OneTouch

Testing my blood sugar is a task I have done faithfully, frequently, and yet without much enthusiasm every day for more than 20 years. It has been like brushing my teeth – I know it’s good for me, so I do it. I’m like a robot. And that’s the problem: I check my blood sugar (at least six times a day), I make a decision in the moment (e.g. take insulin, or treat a low), and then I put the number out of my mind (it’s stored in the meter, right?).

Novo Nordisk to Begin Phase 3 Development of Semaglutide for Type 2 Diabetes

Semaglutide successfully completed phase 2 development in 2010. At that time, it was decided to compare semaglutide with a once-weekly formulation…

Positive Results for Halozyme’s Prandial Insulin Formulations

Halozyme Therapeutics announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes. The study met its primary endpoint of A1C non-inferiority. Further...

Lilly’s Investigational Basal Insulin Shows Better Results than Lantus

Newly Presented results from two Phase II studies of Eli Lilly and Boehringer Ingelheim's investigational novel basal insulin analog, LY2605541, show that that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than Lantus (insulin glargine) in patients...

Lantus Does Not Increase Cancer Risk, New Studies Show

Sanofi has announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California...

New Data Shows Empagliflozin Improves Blood Glucose Levels in Type 2 Diabetes Patients

Eli Lilly and Boehringer Ingelheim presented new data from a phase 2b open-label extension study, showing empagliflozin (BI 10773), alone or as an add-on to metformin, reduced hemoglobin A1c (HbA1c or A1c) levels, fasting plasma glucose (FPG) levels and body weight when given to adults with type 2 diabetes for up to 90 weeks...

New Studies Evaluating Tradjenta, Type 2 Diabetes Treatment

Eli Lilly and Boehringer Ingelheim presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin, marketed under the name Tradjenta in the U.S, at the American Diabetes Association's (ADA) 72nd Scientific Sessions. The new studies...

New Observational Data Shows Patients Prefer Victoza

New data from observational studies in the UK shows that patients with type 2 diabetes experience greater reduction of HbA1c levels when using Victoza compared to Byetta (exenatide) and DPP-4 inhibitors. Victoza...